论文部分内容阅读
研究了低分子肝素口服制剂对实验性高胆固醇血症的预防作用及对食物性高脂蛋白血症的治疗作用。结果表明：低分子肝素口服制剂高、中剂量组小鼠血浆总胆固醇（TC）、低密度脂蛋白胆固醇（LDL－C）较高胆固醇血症对照组小鼠显著降低（P＜0.05），HDL－C／TC显著升高（P＜0.05）；低分子肝素口服制剂高、中剂量组大鼠较高脂蛋白血症对照组大鼠血浆TC、LDL－C显著降低（P＜0．05）．HDL－C／TC显著升高（P＜0．05），高剂量组大鼠血浆甘油三酯（TG）亦显著降低（P＜0．05）。其降血脂作用与藻酸双酯钠相近。
The preventive effect of low molecular weight heparin oral preparations on experimental hypercholesterolemia and its therapeutic effect on food-induced hyperlipoproteinemia were studied. The results showed that the levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in high and middle dose low molecular weight heparin oral administration group were significantly lower than those in control group (P <0.05) (P <0.05). The levels of TC and LDL-C in plasma of rats in high and middle dose low-molecular-weight heparin group were significantly lower than those in hyperlipoproteinemia control group (P <0.05) . HDL-C / TC was significantly increased (P <0.05), and the plasma triglyceride (TG) of high-dose group was significantly lower (P <0.05). Its hypolipidemic effect and sodium alginate similar.